AORT · XBRL financial data

Artivion financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AORT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	253,227	298,836	—	—	—	—
Revenue from contracts with customers	253,227	298,836	313,789	354,004	388,537	441,330
Cost of goods and services sold	85,443	101,322	111,266	124,828	139,756	157,103
Gross profit	167,784	197,514	202,523	229,176	248,781	284,227
Research and development	24,207	35,546	38,879	28,707	28,452	30,991
Selling, general and administrative	141,136	169,774	157,443	208,977	181,455	226,491
Total operating expenses	165,343	205,320	196,322	237,684	209,907	257,482
Operating income (loss)	2,441	8,117	6,201	5,742	38,874	33,745
Interest income	217	79	147	1,077	1,467	763
Interest expense	16,700	16,900	18,224	25,299	34,277	26,582
Other income (expense)	(3,134)	(6,136)	(3,108)	(3,106)	(9,909)	9,518
Income tax expense (benefit)	(492)	7	4,208	9,104	5,845	5,012
Net income (loss)	(16,682)	(14,834)	(19,192)	(30,690)	(13,359)	9,768
Earnings per share, basic USD per share	(0.44)	(0.38)	(0.48)	(0.75)	(0.32)	0.22
Earnings per share, diluted USD per share	(0.44)	(0.38)	(0.48)	(0.75)	(0.32)	0.21
Weighted average shares, basic thousands of shares	37,861	38,983	40,032	40,743	41,676	45,335
Weighted average shares, diluted thousands of shares	37,861	38,983	40,032	40,743	41,676	47,162

Fiscal years (AORT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	61,412	55,010	39,351	58,940	53,463	64,908
Accounts receivable	45,964	53,019	61,820	71,796	79,462	89,758
Inventory	73,038	76,971	74,478	81,976	79,766	92,427
Prepaid and other current assets	14,295	14,748	17,550	15,810	19,257	42,537
Total current assets	234,589	247,697	247,334	280,668	290,080	358,082
Property and equipment, net	33,077	37,521	38,674	38,358	36,403	64,988
Right-of-use asset	18,571	45,714	41,859	43,822	39,726	34,701
Goodwill	260,061	250,000	243,631	247,337	240,958	254,091
Total assets	789,404	793,052	762,798	792,397	789,101	884,796
Accounts payable	9,623	10,395	12,004	13,318	17,971	16,042
Accrued liabilities	7,472	7,687	12,374	12,732	11,834	16,447
Current portion of long-term debt	1,195	1,630	1,608	1,451	195	0
Total current liabilities	60,468	44,953	49,675	57,862	66,823	101,556
Long-term debt	290,468	307,493	306,499	305,531	314,152	215,114
Lease liability, non-current	14,034	44,869	41,257	43,977	39,988	34,427
Total liabilities	460,691	492,324	478,469	510,617	512,901	436,564
Retained earnings (accumulated deficit)	20,022	1,975	(17,217)	(47,907)	(61,266)	(51,498)
Total stockholders' equity	328,713	300,728	284,329	281,780	276,200	448,232
Total liabilities and equity	789,404	793,052	762,798	792,397	789,101	884,796
Common shares outstanding (cover page) thousands of shares	38,957	40,116	40,556	41,225	42,048	47,884

Fiscal years (AORT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(16,682)	(14,834)	(19,192)	(30,690)	(13,359)	9,768
Stock-based compensation	6,912	10,711	12,344	14,422	14,242	24,385
Depreciation and amortization	20,712	23,977	22,442	23,076	24,205	22,458
Net cash from operating activities	12,369	(2,585)	(5,153)	18,825	22,236	39,880
Purchases of property and equipment	7,328	13,091	9,016	7,430	11,188	39,041
Net cash from investing activities	(73,128)	5,660	(10,715)	(502)	(28,188)	(42,041)
Proceeds from issuing common stock	2,432	3,756	3,368	3,955	5,728	13,074
Proceeds from long-term debt	—	—	0	0	184,000	0
Repayments of long-term debt	—	2,786	2,753	2,772	211,831	210
Net cash from financing activities	93,608	(12,223)	(1,639)	865	2,203	11,282
Net change in cash	27,664	(6,948)	(15,659)	19,589	(5,477)	11,445

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Artivion	77,316	125,757	(1,266)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026
Alphatec Holdings	79,936	221,172	18,856*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Tandem Diabetes Care	62,818	254,560	(34,630)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
AtriCure	167,786	153,604	22,192*	50.9M	—	Q2 FY26 10-QJun 30, 2026
CONMED	47,972	335,557	49,411*	29.8M	—	Q3 FY26 10-QSep 30, 2026
Lemaitre Vascular	26,625	not reported	15,965*	22.9M	—	Q2 FY26 10-QJun 30, 2026
Ufp Technologies	9,045	173,964	15,612*	7.7M	—	Q2 FY26 10-QJun 30, 2026
Enovis	12,563	582,782	75,032*	57.7M	—	Q2 FY26 10-QJul 3, 2026
NovoCure	96,734	193,399	22,667	116.9M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.